Nakano Makoto, Sogawa Chiharu Aoki, Sogawa Norio, Mishima Katsuaki, Yamachika Eiki, Mizukawa Nobuyoshi, Fukunaga Joji, Kawamoto Tomoaki, Sawaki Koichi, Sugahara Toshio, Furuta Hiroaki
Department of Oral and Maxillofacial Surgery I, Okayama University Hospital of Dentistry, 2-5-1 Shikata-Cho, Okayama City, Okayama 700-8525, Japan.
Anticancer Res. 2003 Jan-Feb;23(1A):299-303.
Cisplatin (CDDP) is a useful drug for the treatment of malignant solid tumors of the head and neck. Because CDDP includes the heavy metal platinum as a component, it is thought metallothionein (MT) may be involved in CDDP-resistance. However, functional differences between the four MT isoforms (MT-I, II, III and IV) remain unclear. The aim of this study was to investigate the relationship between MT isoform expression and CDDP-resistance. Two human tongue squamous cell carcinoma cell lines not exposed to anticancer chemotherapy were studied. The cell lines were subjected to reverse transcriptase-polymerase chain reaction (RT-PCR) analysis before and after CDDP-treatment. Both cell lines expressed MT-I/II and MT-IV isoforms but not the MT-III isoform. Following CDDP treatment, MT-I/II mRNA levels were induced only in the CDDP-resistant cell line. Our results showed that expression of the MT I/II isoform was induced by CDDP treatment, and may play an important role in CDDP-resistance in squamous cell carcinoma of the human tongue.
顺铂（CDDP）是治疗头颈部恶性实体瘤的一种有效药物。由于CDDP含有重金属铂作为成分，人们认为金属硫蛋白（MT）可能与CDDP耐药有关。然而，四种MT亚型（MT-I、II、III和IV）之间的功能差异仍不清楚。本研究的目的是探讨MT亚型表达与CDDP耐药之间的关系。研究了两个人类舌鳞状细胞癌细胞系，它们未接受过抗癌化疗。在CDDP处理前后，对这些细胞系进行逆转录聚合酶链反应（RT-PCR）分析。两个细胞系均表达MT-I/II和MT-IV亚型，但不表达MT-III亚型。CDDP处理后，MT-I/II mRNA水平仅在CDDP耐药细胞系中被诱导。我们的结果表明，MT I/II亚型的表达可被CDDP处理诱导，并且可能在人类舌鳞状细胞癌的CDDP耐药中起重要作用。
Zotero 插件